Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Liabilities (2016 - 2026)

Myriad Genetics has reported Total Liabilities over the past 16 years, most recently at $338.6 million for Q4 2025.

  • Quarterly Total Liabilities rose 3.71% to $338.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $338.6 million through Dec 2025, up 3.71% year-over-year, with the annual reading at $338.6 million for FY2025, 3.71% up from the prior year.
  • Total Liabilities was $338.6 million for Q4 2025 at Myriad Genetics, down from $355.3 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $465.7 million in Q3 2023 and troughed at $262.8 million in Q2 2022.
  • The 5-year median for Total Liabilities is $347.1 million (2024), against an average of $354.3 million.
  • Year-over-year, Total Liabilities crashed 42.61% in 2022 and then skyrocketed 71.99% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $352.9 million in 2021, then decreased by 11.33% to $312.9 million in 2022, then increased by 16.11% to $363.3 million in 2023, then fell by 10.13% to $326.5 million in 2024, then rose by 3.71% to $338.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Total Liabilities are $338.6 million (Q4 2025), $355.3 million (Q3 2025), and $289.2 million (Q2 2025).